期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 8, 期 4, 页码 511-523出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.4.511
关键词
gemcitabine; palliative; pancreatic carcinoma; targeted therapy; therapy; treatment
类别
Gemcitabine (2',2'-difluorodeoxycytidine) is a deoxycytidine-analog antimetabolite with broad activity against a variety of solid tumors and lymphoid malignancies. It was approved as standard of care in patients with pancreatic cancer one decade ago, based primarily on improvement in clinical benefit response such as pain reduction, improvement in Karnofsky performance status and increase in body weight. This article gives an overview of the pharmacodynamics and pharmacokinetics of gemcitabine, highlights the clinical activity of gemcitabine and summarizes the treatment options in metastastic pancreatic cancer with focus on gemcitabine-based chemotherapy. The emerging role of combinations of gemcitabine with novel targeted agents, including small-molecule inhibitors and other investigational drugs, is also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据